A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hypertriglyceridemia

Interventions

DRUG: Solbinsiran
DRUG: Placebo

Sponsor

Eli Lilly and Company